Overview

Open-label Long-Term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD

Status:
Active, not recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
Open label, flexible dose, long-term multicenter study of safety and efficacy of SPN-812 in adult ADHD patients
Phase:
Phase 3
Details
Lead Sponsor:
Supernus Pharmaceuticals, Inc.